Sinobioway Group Co, Ltd, a major biotech company in China, has been seeking partnerships with US biotech companies through technology and capital investments to help realize its goal of starting a revolution in the bioindustry. Sinobioway and BioAtla LLC, a San Diego-based company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, are working collaboratively to develop several CAB candidates for the Chinese market…Full Article: China Daily June 2016
- In January 2016, both companies (Sinobioway and BioAtla) selected which products to produce and market in China. As a result, Sinobioway Group invested US$19 million in BioAtla, with a total of US$70 million to be invested by the end of 2016.
- In May 2015, China’s Sinobioway Group and California’s BioAtla LLC agreed to collaborate and market CAB proteins for the pharmaceutical industry in China.
- Founded in 1992 and headquartered in Beijing, Sinobioway is a Beijing University affiliated company (one of three) and is one of the country’s leading bio-industry firms. Founded in 1998 and headquartered in Xiamen, Fujian Province, Xiamen Bioway Biotech is a biopharmaceutical company that specializes in high-tech bioengineering and biological agriculture products. The company produces and markets biotech crops such as petunia-CHS (chalcone synthase), pimiento pepper-CMV (cucumber mosaic virus resistance), tomato-CMV, GM rice, and GM tobacco. Xiamen Bioway Biotech is a subsidiary of Sinobioway Group.